| Target Validation Information | |||||
|---|---|---|---|---|---|
| Target ID | T55729 | ||||
| Target Name | Mitogen-activated protein kinase 11 | ||||
| Target Type | Clinical Trial |
||||
| Drug Potency against Target | ML-3403 | Drug Info | IC50 = 990 nM | [1] | |
| RWJ-68354 | Drug Info | IC50 = 7 nM | [2] | ||
| ML-3163 | Drug Info | IC50 = 880 nM | [3] | ||
| ML-3375 | Drug Info | IC50 = 1200 nM | [1] | ||
| BMS-582949 | Drug Info | IC50 = 1.5 nM | [4] | ||
| References | |||||
| REF 1 | J Med Chem. 2003 Jul 17;46(15):3230-44.Novel substituted pyridinyl imidazoles as potent anticytokine agents with low activity against hepatic cytochrome P450 enzymes. | ||||
| REF 2 | Bioorg Med Chem Lett. 2003 Feb 10;13(3):347-50.Imidazopyrimidines, potent inhibitors of p38 MAP kinase. | ||||
| REF 3 | J Med Chem. 2002 Jun 20;45(13):2733-40.From imidazoles to pyrimidines: new inhibitors of cytokine release. | ||||
| REF 4 | Bioorg Med Chem Lett. 2008 Mar 15;18(6):1762-7. Epub 2008 Feb 16.The discovery of (R)-2-(sec-butylamino)-N-(2-methyl-5-(methylcarbamoyl)phenyl) thiazole-5-carboxamide (BMS-640994)-A potent and efficacious p38alpha MAP kinase inhibitor. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.